Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of amyotrophic lateral sclerosis (ALS) globally
3.2.1.2 Growing awareness and early diagnosis of ALS
3.2.1.3 Development of novel drug therapies
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost associated with treatment
3.2.2.2 Side effects associated with treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Medication
5.2.1 Riluzole
5.2.2 Edaravone
5.2.3 Nuedexta
5.2.4 Other medication types
5.3 Stem cell therapy
5.4 Other treatment types
Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Sporadic ALS
6.3 Familial ALS
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Parenteral
Chapter 8 Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospitals
8.3 Rehabilitation centers
8.4 Specialty clinics
8.5 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia-Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia-Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AB Science
10.2 Biogen Inc.
10.3 Biohaven Pharmaceutical (Pfizer, Inc.)
10.4 BrainStorm Therapeutics, Inc.
10.5 Corestemchemon Inc.
10.6 Eledon Pharmaceuticals, Inc.
10.7 F. Hoffmann-La Roche Ltd
10.8 Ionis Pharmaceuticals, Inc.
10.9 ITF Pharma GmbH
10.10 Mitsubishi Tanabe Pharma Corporation
10.11 Otsuka America Pharmaceutical, Inc.
10.12 Sun Pharmaceutical Industries, Ltd.
